AstraZeneca, J&J to work on solution for jabs' blood clot risk problem - report

Tuesday, 13. July 2021 13:21

Johnson & Johnson, AstraZeneca, Oxford University, and independent researchers have joined forces in order to look for possible modifications of the two companies' coronavirus vaccines that would decrease the risk of blood clots, The Wall Street Journal reported on Tuesday, citing sources familiar with the matter.

The research is still at an early stage, the report explained, adding that the scientists hope that AstraZeneca's COVID shot can be "re-engineered" by next year.

"It is too early to know whether either shot can be modified, or whether doing so would make commercial sense," one of the outlet's sources cautioned.

Related Links: Johnson & JohnsonAstraZeneca plc
Breaking the News / BU